Figure 3. Hemoglobin A_1c (HbA_1c) Efficacy Parameters From Baseline to Week 26 Among Patients With Type 2 Diabetes and Insufficient Glycemic Control.

RMM indicates repeated measures model; SC, subcutaneous. A, Data are estimated means from RMM with treatment, stratum, country, and baseline value all nested within visit. Error bars indicate 95% CIs. B, The proportion of patients achieving an HbA_1c level of less than 7.0% after 26 weeks of treatment was significant for the oral semaglutide 2.5-mg group vs placebo (P = .01) and for all other oral semaglutide dosages and SC semaglutide (P < .001). Missing HbA_1c values are imputed from RMM analysis before calculating the proportions of patients reaching the target.

^aNo. of patients with an assessment (panel A) and imputed value (panel B).